BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19221151)

  • 1. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.
    Choi YH; Ahn JH; Kim SB; Jung KH; Gong GY; Kim MJ; Son BH; Ahn SH; Kim WK
    Ann Oncol; 2009 Aug; 20(8):1337-43. PubMed ID: 19221151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
    Wu Y; Mohamed H; Chillar R; Ali I; Clayton S; Slamon D; Vadgama JV
    Breast Cancer Res; 2008; 10(1):R3. PubMed ID: 18184439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer.
    Cao W; Zhang B; Li J; Liu Y; Liu Z; Sun B
    Pathology; 2011 Dec; 43(7):713-8. PubMed ID: 22081131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis.
    Emi Y; Kitamura K; Shikada Y; Kakeji Y; Takahashi I; Tsutsui S
    Surgery; 2002 Jan; 131(1 Suppl):S217-21. PubMed ID: 11821814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
    Wang J; Xu B; Yuan P; Li Q; Zhang P; Cai R; Ma F; Fan Y; Luo Y
    Int J Biol Markers; 2014 Sep; 29(3):e187-92. PubMed ID: 25041784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
    Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
    Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
    Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC
    Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
    Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
    Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.
    Vasconcelos I; Hussainzada A; Berger S; Fietze E; Linke J; Siedentopf F; Schoenegg W
    Breast; 2016 Oct; 29():181-5. PubMed ID: 27544822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
    Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
    J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
    Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
    Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
    Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
    Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HER2 expression and its prognostic implication in lymph node negative breast carcinoma: a Meta-analysis].
    Guo H; Wei B; Zhang HY; Liu GJ; Bu H; Lang ZQ; Tang X; Dai QQ; Chen HJ; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):140-6. PubMed ID: 15938823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.